跳至主要内容
临床试验/NCT02719769
NCT02719769已完成不适用

Evaluation of Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture Identification & Antimicrobial Susceptibility Testing

Accelerate Diagnostics, Inc.14 个研究点 分布在 1 个国家目标入组 4,009 人开始时间: 2016年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
4,009
试验地点
14
主要终点
Comparison Study - ID Performance

研究概览

简要总结

The "Evaluation of Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture Identification & Antimicrobial Susceptibility Testing" is designed to validate the clinical performance of the Accelerate ID/AST System for positive blood culture identification and susceptibility testing in a clinical setting. The data from this study will be used to support the 510(k) submission for FDA clearance and global registrations of the device intended for in vitro diagnostic use.

详细描述

The clinical study entitled "Evaluation of Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture Identification & Antimicrobial Susceptibility Testing" is designed to demonstrate the clinical performance of the Accelerate ID/AST System for positive blood culture identification (ID) and antimicrobial susceptibility testing (AST) in a clinical setting compared to reference results. Approximately 3,000 positive blood culture samples (across all Clinical Sites) will be tested on the investigational device and reference methods. Up to 50% of samples enrolled will be comprised of seeded blood cultures prepared from clinical stock isolates. Quality Control testing will be performed each day of testing. The study population is comprised of left-over clinical specimens that are indicated as positive by blood culture monitoring systems utilized by clinical microbiology laboratories. Positive blood culture samples must be tested on the Accelerate ID/AST System within 8 hours of positivity by the blood culture monitoring system. Testing of clinical samples will continue until the required sample size for each target organism and antimicrobial agent, including sufficient on-scale and resistant strains, are tested across all the sites.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • De-identified positive blood culture specimens (6 mL aliquot)
  • Seeded blood culture specimens (stock) from archived bacterial and yeast isolates

排除标准

  • Sample volume available < 6 mL
  • Positive Blood Culture sample > 8 hours post-positivity
  • Sample from patient previously enrolled
  • Sample from blood culture media that contain charcoal e.g., BACTAlert FA, FN bottles
  • Samples from Mycobacterial-type blood culture media e.g., BACTEC Myco/F Lytic, BacT/ALERT MP Bottle, VersaTREK Myco

结局指标

主要结局

Comparison Study - ID Performance

时间窗: Approximately 9 months (including pre-clinical phase)

Positive and Negative Percent Agreement with Comparator Method (Vitek2) by Bacterial/Fungal Target

次要结局

  • Comparison Study - AST Performance(Approximately 9 months (including pre-clinical phase))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验

Clinical Performance of the Accelerate ID/AST System... | 临床试验